CABOT CORP (CBT) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:CBT • US1270551013

75.93 USD
+0.17 (+0.22%)
At close: Feb 11, 2026
75.93 USD
0 (0%)
After Hours: 2/11/2026, 8:10:20 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

CBT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 83 industry peers in the Chemicals industry. CBT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CBT is valued quite cheap, but it does not seem to be growing. These ratings would make CBT suitable for value investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year CBT was profitable.
  • CBT had a positive operating cash flow in the past year.
  • In the past 5 years CBT has always been profitable.
  • Each year in the past 5 years CBT had a positive operating cash flow.
CBT Yearly Net Income VS EBIT VS OCF VS FCFCBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

1.2 Ratios

  • CBT has a Return On Assets of 8.14%. This is amongst the best in the industry. CBT outperforms 87.95% of its industry peers.
  • Looking at the Return On Equity, with a value of 19.43%, CBT belongs to the top of the industry, outperforming 90.36% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 14.83%, CBT belongs to the top of the industry, outperforming 95.18% of the companies in the same industry.
  • CBT had an Average Return On Invested Capital over the past 3 years of 14.41%. This is significantly above the industry average of 6.08%.
  • The last Return On Invested Capital (14.83%) for CBT is above the 3 year average (14.41%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.14%
ROE 19.43%
ROIC 14.83%
ROA(3y)10.23%
ROA(5y)8.8%
ROE(3y)27.28%
ROE(5y)26.17%
ROIC(3y)14.41%
ROIC(5y)14.64%
CBT Yearly ROA, ROE, ROICCBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.48%, CBT belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.
  • CBT's Profit Margin has improved in the last couple of years.
  • CBT's Operating Margin of 16.50% is amongst the best of the industry. CBT outperforms 81.93% of its industry peers.
  • CBT's Operating Margin has improved in the last couple of years.
  • CBT has a Gross Margin (25.40%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of CBT has grown nicely.
Industry RankSector Rank
OM 16.5%
PM (TTM) 8.48%
GM 25.4%
OM growth 3Y8.11%
OM growth 5Y14.72%
PM growth 3Y22.58%
PM growth 5YN/A
GM growth 3Y7.32%
GM growth 5Y5.51%
CBT Yearly Profit, Operating, Gross MarginsCBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CBT has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for CBT has been reduced compared to 1 year ago.
  • The number of shares outstanding for CBT has been reduced compared to 5 years ago.
  • The debt/assets ratio for CBT has been reduced compared to a year ago.
CBT Yearly Shares OutstandingCBT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CBT Yearly Total Debt VS Total AssetsCBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 3.44 indicates that CBT is not in any danger for bankruptcy at the moment.
  • CBT has a better Altman-Z score (3.44) than 81.93% of its industry peers.
  • The Debt to FCF ratio of CBT is 2.81, which is a good value as it means it would take CBT, 2.81 years of fcf income to pay off all of its debts.
  • CBT's Debt to FCF ratio of 2.81 is amongst the best of the industry. CBT outperforms 87.95% of its industry peers.
  • A Debt/Equity ratio of 0.55 indicates that CBT is somewhat dependend on debt financing.
  • CBT has a Debt to Equity ratio of 0.55. This is in the better half of the industry: CBT outperforms 61.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.81
Altman-Z 3.44
ROIC/WACC1.11
WACC13.37%
CBT Yearly LT Debt VS Equity VS FCFCBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • CBT has a Current Ratio of 1.67. This is a normal value and indicates that CBT is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of CBT (1.67) is worse than 63.86% of its industry peers.
  • CBT has a Quick Ratio of 1.09. This is a normal value and indicates that CBT is financially healthy and should not expect problems in meeting its short term obligations.
  • CBT has a Quick ratio (1.09) which is in line with its industry peers.
  • The current and quick ratio evaluation for CBT is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.09
CBT Yearly Current Assets VS Current LiabilitesCBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • CBT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.17%.
  • Measured over the past years, CBT shows a very strong growth in Earnings Per Share. The EPS has been growing by 28.53% on average per year.
  • Looking at the last year, CBT shows a decrease in Revenue. The Revenue has decreased by -9.62% in the last year.
  • Measured over the past years, CBT shows a small growth in Revenue. The Revenue has been growing by 7.27% on average per year.
EPS 1Y (TTM)-3.17%
EPS 3Y5.06%
EPS 5Y28.53%
EPS Q2Q%-13.07%
Revenue 1Y (TTM)-9.62%
Revenue growth 3Y-4.93%
Revenue growth 5Y7.27%
Sales Q2Q%-11.1%

3.2 Future

  • CBT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.89% yearly.
  • The Revenue is expected to grow by 1.96% on average over the next years.
EPS Next Y-10.14%
EPS Next 2Y-0.26%
EPS Next 3Y2.54%
EPS Next 5Y4.89%
Revenue Next Year-4.96%
Revenue Next 2Y-1.12%
Revenue Next 3Y0.68%
Revenue Next 5Y1.96%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CBT Yearly Revenue VS EstimatesCBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
CBT Yearly EPS VS EstimatesCBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 10.80, the valuation of CBT can be described as very reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of CBT indicates a rather cheap valuation: CBT is cheaper than 90.36% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 28.18, CBT is valued rather cheaply.
  • A Price/Forward Earnings ratio of 10.51 indicates a reasonable valuation of CBT.
  • 91.57% of the companies in the same industry are more expensive than CBT, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.01, CBT is valued rather cheaply.
Industry RankSector Rank
PE 10.8
Fwd PE 10.51
CBT Price Earnings VS Forward Price EarningsCBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CBT is valued cheaper than 86.75% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CBT indicates a rather cheap valuation: CBT is cheaper than 87.95% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.89
EV/EBITDA 6.44
CBT Per share dataCBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • CBT has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.38
EPS Next 2Y-0.26%
EPS Next 3Y2.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • CBT has a Yearly Dividend Yield of 2.37%.
  • CBT's Dividend Yield is a higher than the industry average which is at 2.20.
  • Compared to an average S&P500 Dividend Yield of 1.80, CBT pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.37%

5.2 History

  • The dividend of CBT has a limited annual growth rate of 4.94%.
  • CBT has paid a dividend for at least 10 years, which is a reliable track record.
  • CBT has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)4.94%
Div Incr Years13
Div Non Decr Years34
CBT Yearly Dividends per shareCBT Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • 31.37% of the earnings are spent on dividend by CBT. This is a low number and sustainable payout ratio.
  • CBT's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP31.37%
EPS Next 2Y-0.26%
EPS Next 3Y2.54%
CBT Yearly Income VS Free CF VS DividendCBT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M
CBT Dividend Payout.CBT Dividend Payout, showing the Payout Ratio.CBT Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CABOT CORP

NYSE:CBT (2/11/2026, 8:10:20 PM)

After market: 75.93 0 (0%)

75.93

+0.17 (+0.22%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-03
Earnings (Next)05-04
Inst Owners99.5%
Inst Owner Change-1.53%
Ins Owners1.26%
Ins Owner Change5.46%
Market Cap3.97B
Revenue(TTM)3.61B
Net Income(TTM)306.00M
Analysts73.33
Price Target72.22 (-4.89%)
Short Float %3.85%
Short Ratio4.08
Dividend
Industry RankSector Rank
Dividend Yield 2.37%
Yearly Dividend1.79
Dividend Growth(5Y)4.94%
DP31.37%
Div Incr Years13
Div Non Decr Years34
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.8%
Min EPS beat(2)0.03%
Max EPS beat(2)7.57%
EPS beat(4)4
Avg EPS beat(4)3.06%
Min EPS beat(4)0.03%
Max EPS beat(4)7.57%
EPS beat(8)7
Avg EPS beat(8)3.45%
EPS beat(12)10
Avg EPS beat(12)2.77%
EPS beat(16)14
Avg EPS beat(16)4.17%
Revenue beat(2)0
Avg Revenue beat(2)-6.3%
Min Revenue beat(2)-7.35%
Max Revenue beat(2)-5.24%
Revenue beat(4)0
Avg Revenue beat(4)-6.6%
Min Revenue beat(4)-9.48%
Max Revenue beat(4)-4.31%
Revenue beat(8)1
Avg Revenue beat(8)-4.54%
Revenue beat(12)1
Avg Revenue beat(12)-5.03%
Revenue beat(16)5
Avg Revenue beat(16)-1.91%
PT rev (1m)3.21%
PT rev (3m)-19.09%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)-7.42%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)-17.39%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-3.23%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-8.1%
Valuation
Industry RankSector Rank
PE 10.8
Fwd PE 10.51
P/S 1.1
P/FCF 9.89
P/OCF 5.94
P/B 2.52
P/tB 2.86
EV/EBITDA 6.44
EPS(TTM)7.03
EY9.26%
EPS(NY)7.22
Fwd EY9.51%
FCF(TTM)7.68
FCFY10.11%
OCF(TTM)12.77
OCFY16.82%
SpS69.07
BVpS30.16
TBVpS26.52
PEG (NY)N/A
PEG (5Y)0.38
Graham Number69.07
Profitability
Industry RankSector Rank
ROA 8.14%
ROE 19.43%
ROCE 20.64%
ROIC 14.83%
ROICexc 16.11%
ROICexgc 17.35%
OM 16.5%
PM (TTM) 8.48%
GM 25.4%
FCFM 11.12%
ROA(3y)10.23%
ROA(5y)8.8%
ROE(3y)27.28%
ROE(5y)26.17%
ROIC(3y)14.41%
ROIC(5y)14.64%
ROICexc(3y)15.7%
ROICexc(5y)15.9%
ROICexgc(3y)16.88%
ROICexgc(5y)17.3%
ROCE(3y)20.49%
ROCE(5y)21.33%
ROICexgc growth 3Y1.98%
ROICexgc growth 5Y16.93%
ROICexc growth 3Y2.08%
ROICexc growth 5Y17.96%
OM growth 3Y8.11%
OM growth 5Y14.72%
PM growth 3Y22.58%
PM growth 5YN/A
GM growth 3Y7.32%
GM growth 5Y5.51%
F-Score6
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.81
Debt/EBITDA 1.15
Cap/Depr 168.35%
Cap/Sales 7.37%
Interest Coverage 250
Cash Conversion 88.58%
Profit Quality 131.05%
Current Ratio 1.67
Quick Ratio 1.09
Altman-Z 3.44
F-Score6
WACC13.37%
ROIC/WACC1.11
Cap/Depr(3y)168.99%
Cap/Depr(5y)154.67%
Cap/Sales(3y)6.54%
Cap/Sales(5y)6.04%
Profit Quality(3y)106.95%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.17%
EPS 3Y5.06%
EPS 5Y28.53%
EPS Q2Q%-13.07%
EPS Next Y-10.14%
EPS Next 2Y-0.26%
EPS Next 3Y2.54%
EPS Next 5Y4.89%
Revenue 1Y (TTM)-9.62%
Revenue growth 3Y-4.93%
Revenue growth 5Y7.27%
Sales Q2Q%-11.1%
Revenue Next Year-4.96%
Revenue Next 2Y-1.12%
Revenue Next 3Y0.68%
Revenue Next 5Y1.96%
EBIT growth 1Y-6%
EBIT growth 3Y2.78%
EBIT growth 5Y23.06%
EBIT Next Year11.6%
EBIT Next 3Y8.03%
EBIT Next 5YN/A
FCF growth 1Y4.16%
FCF growth 3YN/A
FCF growth 5Y17.18%
OCF growth 1Y2.93%
OCF growth 3Y88.05%
OCF growth 5Y12.02%

CABOT CORP / CBT FAQ

What is the ChartMill fundamental rating of CABOT CORP (CBT) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CBT.


What is the valuation status of CABOT CORP (CBT) stock?

ChartMill assigns a valuation rating of 8 / 10 to CABOT CORP (CBT). This can be considered as Undervalued.


Can you provide the profitability details for CABOT CORP?

CABOT CORP (CBT) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for CBT stock?

The Price/Earnings (PE) ratio for CABOT CORP (CBT) is 10.8 and the Price/Book (PB) ratio is 2.52.


How financially healthy is CABOT CORP?

The financial health rating of CABOT CORP (CBT) is 8 / 10.